Table 7. Distribution of OTSCC immunohistochemical prognostic biomarkers studies according to countries.
|
Number of studies (HR and CI were reported in the study for at least one survival endpoint) |
|||||
|---|---|---|---|---|---|
| Country | p53 | Ki-67 | p16 | VEGFs | Cyclin D1 |
| Japan | 4 (2)a | 4 (2) | 2 (1)a | 5 (3)a | 5 (0) |
| USA | 4 (0) | 1 (1) | 2 (1)a | – | – |
| India | 3 (2)a | – | 4 (2)b | – | 2 (1)a |
| China | 2 (0) | – | 1 (0) | 1 (1)a | 1 (0) |
| Korea | 1 (0) | 1 (1) | – | 3 (0) | – |
| Australia | 1 (1)a | 1 (1)a | 2 (2)b | – | 1 (1)a |
| Finland | 1 (0) | 1 (1)a | – | – | – |
| Iran | – | – | – | – | – |
| Norway | 1 (0) | 1 (0) | – | – | – |
| Sweden | 1 (1) | 1 (0) | 1 (0) | – | – |
| Tunisia | 1 (0) | 1 (0) | – | – | – |
| Turkey | 1 (0) | – | – | – | – |
| Brazil | – | 2 (0) | – | – | 1 (0) |
| Czech | – | – | 1 (0) | 1 (1)a | – |
| Spain | – | – | 1 (0) | – | – |
| USA & China | – | 1 (1)a | – | – | – |
| Finland & Israel | – | 1 (1) | – | – | – |
| Total number of studies | 20 | 15 | 14 | 10 | 10 |
The entries are total numbers of studies and in parentheses are given numbers of studies in which the hazard ratio and its 95% confidence interval were reported for at least one survival endpoint.
a
Only one study from this country was included in the meta-analysis of overall survival.
b
Two studies from India and two studies from Australia were included in the meta-analysis of p16.